Toronto Dominion Bank
CBAY

Toronto Dominion Bank’s Cymabay Therapeutics CBAY Stock Holding History

Toronto Dominion Bank’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8
Closed – – 2009
2022
Q1 		$0 Hold
8
– – ﹤0.01% 2132
2021
Q4 		$0 Buy
+8
New +$30 ﹤0.01% 2120

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Toronto Dominion Bank's CBAY Position: Q2 2022 in Review

Toronto Dominion Bank sold out of Cymabay Therapeutics (CBAY) in Q2 2022, closing a stake of 8 shares.

Toronto Dominion Bank first reported a position in CBAY in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 106 funds tracked by Wall St. Rank hold CBAY as of Q2 2022.

  • Toronto Dominion Bank reported no remaining Cymabay Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Toronto Dominion Bank sold 8 Cymabay Therapeutics shares in Q2 2022.
  • Toronto Dominion Bank first reported a position in Cymabay Therapeutics in Q4 2021 and held it in 2 quarters.
  • Toronto Dominion Bank's Cymabay Therapeutics position peaked at $0 in Q1 2022.
  • 106 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2022.

Based on Toronto Dominion Bank's 13F filing for Q2 2022, filed 11 Aug 2022.